Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 197 | 50% |
| 2020 | 0 | 175 | 51% |
| 2021 | 1 | 164 | 53% |
| 2022 | 0 | 117 | 56% |
| 2023 | 0 | 153 | 58% |
| 2024 | 0 | 153 | 59% |
| 2025 from claims | – | 239 193–280 | 59% |
| 2026 forecast | – | 250 196–314 | 58% |
| 2027 forecast | – | 258 191–341 | 58% |
| 2028 forecast | – | 265 188–366 | 58% |
| 2029 forecast | – | 273 185–391 | 58% |
| 2030 forecast | – | 281 184–417 | 58% |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 3 | 1,597−4.2%/yr | −4.2%/yr | 0.5 | 0% | 1,700 in 2030+1%/yr |
| Washington | 3 | 433−0.5%/yr | −0.5%/yr | 0.6 | 0% | 440 in 2030+0.2%/yr |
| Arizona | 2 | 409−4.1%/yr | −4.1%/yr | 0.6 | 0% | 400 in 2030−0.5%/yr |
| Colorado | 0 | 158−8.8%/yr | −8.8%/yr | 0.3 | 0% | 190 in 2030+3.2%/yr |
| New Mexico | 2 | 123−0.2%/yr | −0.2%/yr | 0.5 | 0% | 80 in 2030−6.1%/yr |
| Nevada | 0 | 118−7.9%/yr | −7.9%/yr | 0.4 | 0% | 200 in 2030+9.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 40 | 1,758−7.7%/yr | −7.7%/yr | 3.40.7× | 2% | 1,840 in 2030+0.7%/yr |
| Structural heart (TAVR, TEER) | 39 | 802+2.6%/yr | +2.6%/yr | 1.61.1× | 0% | 1,140 in 2030+6%/yr |
Mechanical circulatory support in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
No company payments named for these products in Oregon in 2025.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.